C
12.79
-0.24 (-1.84%)
| Previous Close | 13.03 |
| Open | 12.96 |
| Volume | 3,307,572 |
| Avg. Volume (3M) | 3,251,179 |
| Market Cap | 954,760,704 |
| Price / Earnings (TTM) | 16.40 |
| Price / Earnings (Forward) | 6.25 |
| Price / Sales | 6.95 |
| Price / Book | 4.38 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CorMedix Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.80 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 34.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (JMP Securities, 72.01%) | Buy |
| Median | 17.00 (32.92%) | |
| Low | 15.00 (D. Boral Capital, 17.28%) | Buy |
| Average | 18.20 (42.30%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 13.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 09 Sep 2025 | 22.00 (72.01%) | Buy | 13.03 |
| HC Wainwright & Co. | 08 Aug 2025 | 17.00 (32.92%) | Buy | 10.33 |
| 30 Jun 2025 | 20.00 (56.37%) | Buy | 12.32 | |
| Needham | 24 Jun 2025 | 20.00 (56.37%) | Buy | 15.72 |
| D. Boral Capital | 23 Jun 2025 | 15.00 (17.28%) | Buy | 16.56 |
| RBC Capital | 20 Jun 2025 | 17.00 (32.92%) | Buy | 13.61 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HURLBURT ELIZABETH | - | 13.06 | -53,997 | -706,048 |
| ZELNICK KAUFMAN BETH | - | 13.03 | -50,000 | -651,500 |
| Aggregate Net Quantity | -103,997 | |||
| Aggregate Net Value ($) | -1,357,548 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.05 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HURLBURT ELIZABETH | Officer | 11 Sep 2025 | Sell (-) | 41,121 | 13.09 | 538,274 |
| HURLBURT ELIZABETH | Officer | 11 Sep 2025 | Option execute | 41,121 | - | - |
| HURLBURT ELIZABETH | Officer | 09 Sep 2025 | Sell (-) | 12,876 | 13.03 | 167,774 |
| HURLBURT ELIZABETH | Officer | 09 Sep 2025 | Option execute | 12,876 | - | - |
| ZELNICK KAUFMAN BETH | Officer | 09 Sep 2025 | Sell (-) | 50,000 | 13.03 | 651,500 |
| ZELNICK KAUFMAN BETH | Officer | 09 Sep 2025 | Option execute | 50,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |